MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

CAS No. : 1797989-42-4

MCE 國際站：Laduviglusib monohydrochloride

產品活性：Laduviglusib (CHIR-99021) monohydrochloride 是一種有效的選擇性 GSK-3α/β 抑制劑，IC₅₀ 為 10 nM 和 6.7 nM。Laduviglusib monohydrochloride 對 GSK-3 的選擇性比 CDC2，ERK2 和其他蛋白激酶高 500 倍以上。Laduviglusib monohydrochloride 還是一種有效的 Wnt/β-catenin 信號通路激活劑。Laduviglusib monohydrochloride 可增強小鼠和人類胚胎干細胞的自我更新。Laduviglusib monohydrochloride 能誘導細胞自噬 (autophagy)。

研究領域：PI3K/Akt/mTOR  |  Stem Cell/Wnt  |  Autophagy

作用靶點：GSK-3  |  Wnt  |  β-catenin  |  Autophagy

In Vitro: Laduviglusib monohydrochloride inhibits human GSK-3β with K_i values of 9.8 nM. Laduviglusib monohydrochloride is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites. In vitro kinase assays reveal that Laduviglusib monohydrochloride specifically inhibits GSK3β (IC₅₀=~5 nM) and GSK3α (IC₅₀=~10 nM), with little effect on other kinases. In the presence of Laduviglusib monohydrochloride the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib monohydrochloride with an IC₅₀ of 4.9 μM.

In Vivo: In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) monohydrochloride rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration. Laduviglusib (2 mg/kg) monohydrochloride given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib monohydrochloride treatment significantly blocks crypt apoptosis and accumulation of p-H2AX⁺ cells, and improves crypt regeneration and villus height. Laduviglusib monohydrochloride treatment increases Lgr5⁺ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h.

相關產品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Wnt/Hedgehog/Notch Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Diabetes Related Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Anti-Alzheimer's Disease Compound Library  |  Neuroprotective Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Transcription Factor Targeted Library  |  Glucose Metabolism Compound Library  |  Laduviglusib  |  XAV-939  |  IWR-1  |  IWP-2  |  ICG-001  |  SB 216763  |  Wnt-C59  |  Pyrvinium pamoate  |  Salinomycin  |  LY2090314  |  SKL2001  |  BML-284  |  Tideglusib  |  Heparan Sulfate  |  AR-A014418  |  TDZD-8  |  Adavivint  |  TWS119  |  NCB-0846  |  Kenpaullone  |  GSK 3 Inhibitor IX  |  Toxoflavin  |  MSAB  |  HLY78  |  iCRT3  |  Wogonin  |  FH535  |  LF3

熱門產品線：重組蛋白  |  化合物庫  |  天然產物  |  染料試劑  |  PROTAC  |  同位素標記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介紹:
•   MCE (MedChemExpress) 擁有數百種全球獨家化合物，我們致力于為全球科研客戶提供最新最全的高品質小分子活性化合物；
•   10,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領域；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
•   專業團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球最新的活性化合物；
•   與世界各大制藥公司及知名科研機構建立了長期的合作。